Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG:6990)

Market Cap	86.23B +112.6%
Revenue (ttm)	1.64B -20.1%
Net Income	-791.34M
EPS	-3.51
Shares Out	233.19M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	755,911
Average Volume	446,584
Open	358.80
Previous Close	348.00
Day's Range	355.80 - 376.80
52-Week Range	225.20 - 581.00
Beta	0.45
RSI	37.98
Earnings Date	Mar 24, 2026

About HKG:6990

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, and other therapeutic areas in the People’s Republic of China and internationally. Its product pipeline includes Sac-TMT, a novel TROP2 ADC positioned as a monotherapy and part of combination therapies for treating various advanced solid tumors; Trastuzumab botidotin, a monotherapy to treat advanced HER2+ solid tumors; SKB315, a novel CLDN18.2 ADC ta...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 1,870
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6990

Financial Performance

In 2024, HKG:6990's revenue was 1.93 billion, an increase of 25.48% compared to the previous year's 1.54 billion. Losses were -266.77 million, -48.92% less than in 2023.

Financial numbers in CNY